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Abstract 
Human mesenchymal stromal cells (hMSCs) offer great potential for bone tissue engineering 
applications, but their in vivo performance remains limited. Pre-conditioning of these cells 
with small molecules to improve their differentiation prior to implantation or incorporation of 
growth factors are possible solutions. Insulin-like growth factor-1 (IGF-1) is one of the most 
abundant growth factors in bone, involved in growth, development and metabolism, but its 
effects on hMSCs are still subject of debate. Herein, we examined the effects of IGF-1 on 
proliferation and differentiation of hMSCs in vitro and we found that serum abolished the 
effects of IGF-1. Only in the absence of serum, IGF-1 increased proliferation, ALP expression 
and osteogenic gene expression of hMSCs. Furthermore, we examined synergistic effects of 
BMP-2 and IGF-1 and, although IGF-1 enhanced BMP-2-induced mineralization, IGF-1 only 
slightly affected in vivo bone formation. 
Key words: bone tissue engineering, osteogenic differentiation, mesenchymal stem cells, 
insulin-like growth factor 1, bone-morphogenetic protein 2 
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Introduction 
Cell-based bone tissue engineering aims to construct substitutes for large bone defects. 
Human mesenchymal stromal cells (hMSCs) are one of the most interesting cell sources for 
this application, due to their easy isolation, their presence in the adult body and their capacity 
to proliferate and differentiate. However, so far the in vivo performance of these cells is 
limited. Studies using human MSCs have resulted in limited amounts of newly formed bone 
[15-17] and in order to improve the therapeutic efficacy various strategies have been 
employed. Researchers have differentiated hMSCs prior to implantation by treating the cells 
with compounds that induce osteogenic differentiation. It was shown that pre-differentiation 
with dexamethasone can increase bone formation by hMSCs [17], whereas other compounds 
such as trichostatin A [18] and lithium [19], which did induce osteogenic differentiation, did 
not affect bone formation in vivo. Thus, so far, better results are obtained by co-implantation 
of the cells with osteoinductive growth factors such as bone morphogenetic protein-2 (BMP-
2) [14]. 
Insulin-like-growth-factor-I (IGF-I or somatomedin C) is one of the most abundant growth 
factors in the bone matrix, involved in growth, development and metabolism. It is produced 
locally as well as systemically by the liver and its biological actions are regulated by the acid-
labile subunit (ALS) and six binding proteins (IGFBPs), which can either enhance or inhibit 
its actions by preventing access to the IGF-I receptor (IGFR-I) [1]. Systemic production of 
IGF-1 by the liver is regulated by growth hormone (GH) and this system is thus referred to as 
the GH/IGF-1 axis [2, 3]. Locally, IGF-1 is produced by a variety of cell types, which is 
regulated not only by GH but also by numerous other factors.  
Several mouse models have demonstrated a key role of IGF-1 in bone formation [4, 5]. 
Complete disruption of IGF signaling, by deletion of the IGFR-I results in a reduction of 
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cancellous bone volume, connectivity and trabecular number and increases trabecular spacing 
[6]. Interestingly, these mice display a dramatic decrease in mineralization, indicating an 
essential role for IGF-1 in the development of mature mineralized tissue [6]. IGF-1 null mice 
have reduced cortical bone size and femur length, although an increase in trabecular bone 
density and connectivity were also observed [7]. Impaired osteoclastogenesis may explain the 
latter findings, in line with in vitro studies showing that IGF-1 promotes osteoclastogenesis 
[7, 8]. Local overexpression of IGF-1 in osteoblasts resulted in increased bone mineral density 
and trabecular bone volume [9] and, since no increase in osteoblast number was observed, the 
effects of IGF-1 were suggested to be mediated via enhanced osteoblast function.  
Due to its positive effect on osteoblasts, its presence at fracture sites and its involvement in 
the synthesis of bone matrix [10], IGF-1 has gained interest as a therapeutic factor in fracture 
healing; either alone or in combination with other growth factors. In vitro IGF-1 was shown to 
enhance proliferation of C2C12 cells, osteoblasts [11], osteoblast-like cells [12] and 
periodontal ligament fibroblasts [13]. It also induces alkaline phosphatase (ALP) activity, 
osteocalcin, matrix calcium content, and nodule formation in osteoblasts [14] and has been 
proven as a chemotactic factor for these cells [15]. Furthermore, in fetal rat calvariae, IGF-1 
was shown to enhance osteocalcin secretion and incorporation of proline into collagen type I 
[16] and to decrease collagen degradation [17].  
In hMSCs, similar effects of IGF-1 on migration were shown [18, 19], but the effects of IGF-
1 on proliferation and differentiation are less clear. Some studies show that IGF-1 does not 
affect hMSCs at all [20, 21], whereas on the other hand, MSCs transduced with an IGF-1 
adenovirus displayed increased runx2 and collagen type I expression, but not ALP [22]. Also, 
incorporation of IGF-1 in scaffolds enhanced proliferation and differentiation of attached 
hMSCs and periodontal ligament fibroblasts [23, 24]. In contrast, it has been reported that 
IGF-1 stimulates chondrogenic differentiation of hMSCs in the presence of TGF-β [25], 
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which was also demonstrated by adenoviral overexpression of IGF-1 and bone morphogenetic 
protein-2 (BMP-2) in adipose-derived MSCs [26]. In our own lab, we have shown that 
treatment of hMSCs with the small molecule db-cAMP enhances in vivo bone formation, 
which is accompanied by increased secretion of bone specific growth factors, such as BMP-2, 
but also IGF-1 [27]. Conditioned medium from these treated cells increased proliferation of 
various cell types, thus indicating a trophic effect [28], but it is unknown if secreted IGF-1 
can affect the implanted hMSCs. 
In this study we examined the effects of IGF-1 on proliferation and differentiation of hMSCs, 
both in the presence and absence of serum, which may contain proteins that neutralize IGF-1 
function. In addition, with an adenoviral transduction system, we investigated if IGF-1 has 
effects on in vivo bone forming capacity of hMSCs, either alone or in combination with BMP-
2. 
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Materials and methods 
Cell culture 
Bone marrow aspirates (5-20 ml) were obtained from donors with written informed consent. 
hMSCs were isolated and proliferated as described previously [29]. Briefly, aspirates were re-
suspended using 20 G needles, plated at a density of 5x10
5
 cells/cm
2
 and cultured in hMSC 
proliferation medium containing -minimal essential medium (-MEM, Life Technologies), 
10% fetal bovine serum (FBS, Cambrex), 0.2 mM ascorbic acid (Asap, Life Technologies), 2 
mM L-glutamine (Life Technologies), 100 U/ml penicillin (Life Technologies), 10 g/ml 
streptomycin (Life Technologies) and 1 ng/ml basic fibroblast growth factor (bFGF, 
Instruchemie, The Netherlands). Cells were grown at 37
°
C in a humid atmosphere with 5% 
CO2. Medium was refreshed twice a week and cells were used for further sub-culturing or 
cryopreservation upon reaching near confluence. For osteogenic experiments, hMSCs were 
cultured in basic medium, composed of hMSC proliferation medium without bFGF. The 
osteosarcoma cell line MG-63 was expanded and cultured in basic medium as described 
above. Recombinant human insulin-like growth factor-I (rhIGF-1) was obtained from R&D 
systems and used in concentrations between 10 and 150 ng/mL. Recombinant human bone 
morphogenetic protein-2 (rhBMP-2) was obtained from Biodoor Biotechnology co., Ltd 
(Hangzhou, China) and used at a concentration of 100 ng/mL, unless stated otherwise. 
Proliferation 
hMSCs or MG-63 cells were seeded in triplicate in 24-well plates at 2000 cells/cm
2
 and 
allowed to attach for 10 to 15 hours in proliferation medium or basic medium respectively. 
Then, the medium was changed to basic medium with or without FBS with various 
concentrations of rhIGF-1. After 5 days an Alamar Blue assay (BioSource) was performed. A 
10% v/v solution of Alamar Blue in medium was prepared and 1 mL of solution was added to 
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each well. After 4 hours, the fluorescence intensity of the solution in each well was 
determined by measuring 200 µL of solution at an excitation wavelength of 545 nm and an 
emission wavelength of 590 nm (Victor, Perkin Elmer). 
ALP expression 
hMSCs were seeded in triplicate in 6-well plates at 5000 cells/cm
2
 and allowed to attach for 
10 to 15 hours in proliferation medium. Each experiment was performed in triplicate with a 
negative control (cells grown in basic medium) and one or more experimental conditions 
(with or without FBS, various concentrations of IGF-1). After 4 days, cells were trypsinized 
and incubated for 30 minutes in block buffer (PBS with 5% bovine serum albumin, BSA 
[Sigma] and 0.01% NaN3) and then incubated with primary antibody (anti-ALP, B4-78 
[Developmental Studies Hybridoma Bank, University of Iowa, USA]) diluted in wash buffer 
(PBS with 1% BSA and 0.05% NaN3) for 1 hour or with isotype control antibodies. Cells 
were then washed three times with wash buffer and incubated with secondary antibody (rat 
anti mouse IgG PE, DAKO) diluted in wash buffer for 30 minutes. Cells were washed three 
times and resuspended in 250 μl wash buffer with 10 μl Viaprobe (Pharmingen) for live/dead 
cell staining. Only living cells were used for further analysis. With the isotypes set to zero, the 
amount of ALP-positive cells were analyzed on a FACS Caliber using cell-quest software 
(Becton Dickinson Immunocytometry systems). ALP expression was then calculated relative 
to the respective negative control.  
ALP activity 
MG-63 cells were seeded in triplicate in 12-well plates at 5000 cells/cm
2
 and allowed to 
attach for 10-15 hours. The next day, medium was changed to medium with or without FBS, 
with various concentrations of IGF-1. As a negative control, cells were cultured in basic 
medium. After 4 days of culture an Alamar Blue assay was performed. Then, cells were lysed 
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with CDP star lysis buffer and the lysate was used for a CDP star assay (Roche). Briefly, 30 
µL of CDP star substrate was incubated with 10 µL of cell lysate for 30 minutes after which 
luminescence was measured (Victor, Perkin Elmer). ALP expression was normalized to 
metabolic activity, and data is depicted as percentage relative to control. 
Calcium deposition  
Cells were seeded in triplicate in 6-well plates at 5000 cells/cm
2
 and allowed to attach for 10 
to 15 hours in proliferation medium. Then, either mineralization medium alone (composed of 
basic medium supplemented with 10
-8 
M dex and 0.01 M -glycerophosphate (Sigma)) or 
mineralization medium supplemented with 75 ng/mL BMP-2, 100 ng/mL IGF-1 or a 
combination of both was added and cells were kept in culture for 14-21 days. Then, culture 
medium was aspirated, cells were washed twice with calcium- and magnesium-free PBS (Life 
Technologies) and incubated overnight with 0.5 M HCl on an orbital shaker at room 
temperature. Then the supernatant was collected and the amount of calcium was determined 
using a calcium assay kit (Quantichrom calcium assay kit, Gentaur), by measuring the 
absorbance at 620 nm (Tecan). Data is depicted as dg calcium per mL HCl.  
Gene expression analysis 
Cells were seeded in triplicate in 6-well plates at 10,000 cells/cm
2 
in proliferation medium. 
The next day, medium was replaced with basic medium with or without serum, and 100 
ng/mL IGF-1 was added to denoted conditions. RNA was isolated after 24 hrs, 48 hrs, 72 hrs, 
5 days and 10 days, using a Bioke RNA II nucleospin RNA isolation kit (Machery Nagel). 
For gene overexpression experiments, cells were kept in culture for 2 or 5 days after medium 
change and RNA was isolated. RNA concentrations were measured using an ND100 
spectrophotometer (Nanodrop technologies, USA) and cDNA was synthesized from 100 ng of 
RNA, using iScript (BioRad) according to the manufacturer’s protocol. For quantitative PCR, 
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a master mix, containing distilled water, forward primer, reverse primer (Sigma Genosys), 
BSA, and SYBR green I mix (all from Invitrogen) was prepared. Real-time qPCR was 
performed in a Light-Cycler (Roche). Light-Cycler data were analyzed using the fit points 
method of Light-Cycler software [30]. The baseline was set at the lower log-linear part above 
baseline noise and the crossing temperature (Ct value) was determined. Ct values were 
normalized to the 18S housekeeping gene and ΔCt (Ct, control – Ct, sample) was used to calculate 
the relative increase in gene expression. Primer sequences are listed in table 1. 
Confocal Raman microspectroscopy 
UV grade CaF2 slides for Raman (Crystran LTD, UK) were sterilized using 70% ethanol and 
subsequently coated with proteins by incubation with FBS for 30 minutes. Then, hMSCs were 
seeded in triplicate at 5000 cells/cm
2
 and allowed to attach overnight in proliferation medium. 
The next day, medium was replaced with mineralization medium, with and without IGF-1 
(100 ng/mL) and BMP-2 (100 ng/mL). After 28 days of culture, cells were fixed using 10% 
formalin and Raman spectra were acquired. A krypton ion laser (Innova 90-K, Coherent Inc.) 
emitting at 647.1 nm was used as an excitation source. A 63x/1.0NA water-dipping objective 
(Zeiss W-plan Apochromat, Carl Zeiss MicroImaging) was used to focus the laser light over 
the sample and the Raman scattered photons were collected and dispersed on an air-cooled 
electron-multiplying charge-coupled device (EMCCD: Newton DU-970N, Andor 
Technology). An excitation power of 35mW on the sample was used. Raman spectra were 
acquired from 15 randomly chosen cells in each culture condition. 
Scanning electron microscopy 
Cells were seeded in triplicate in 6-well plates at 5000 cells/cm
2 
in proliferation medium. The 
next day, medium was replaced with basic medium with or without 100 ng/mL IGF-1 and / or 
100 ng/mL BMP-2. After 10 and 17 days of culture, cells were fixed using 10% formalin. 
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Samples were dehydrated through a graded series of ethanol (70-100%), critical point dried 
using CO2 (CPD 030, Balzers) and sputtered with gold (Cressington). SEM images were 
obtained using a scanning electron microscope (XL30 ESEM, Philips) at an accelerating 
voltage of 5 or 10 kV. 
Adenoviral transductions 
Adenovirusses containing an expression vector for IGF-1 (adIGF-1), BMP-2 (adBMP-2) or 
green fluorescent protein (adGFP, control) were purchased from Biofocus (Leiden, The 
Netherlands). For adenoviral transductions, hMSCs were seeded at 15,000 cells/cm
2
 and 
allowed to attach overnight. The next day, cells were transduced in basic medium using a 
previously optimized (data not shown) multiplicity of infection (MOI) of 1000 for adIGF-1 
and adGFP and an MOI of 250 for adBMP-2 for 24 hours, after which the medium was 
replaced with fresh medium. Transduced cells were then used for further in vitro experiments 
or, in case of the in vivo experiments, trypsinized, and seeded onto ceramic scaffolds for 
implantation. 
Secretion of IGF-1 and BMP-2  
hMSCs were seeded and transduced as described above. After the medium change, every 3 
days medium was collected and replaced with fresh medium for a total period of 15 (control 
for in vitro experiments) or 30 (control for in vivo experiment) days. The concentrations of 
IGF-1 and/or BMP-2 in the medium were determined using ELISA (human IGF-1/BMP-2, 
Quantikine, R&D systems), according to the manufacturer’s protocol.  
In vivo bone formation 
1-2 mm biphasic calcium phosphate (BCP) particles were prepared and sintered at 1150 
0
C as 
described previously [31]. hMSCs were seeded and transduced as described above. The next 
day, cells were trypsinized and seeded onto BCP scaffolds with 200,000 cells/4 particles in 
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basic medium and allowed to attach overnight. 20 minutes before surgery, nude female mice 
(Hsd-cpb:NMRI-nu, Harlan) were injected intraperitoneally with avertin. Particles were 
implanted in subcutaneous pockets, with 4 particles per pocket, 4 pockets per mouse and 10 
samples per condition. Incisions were closed using surgical staples and after 6 weeks the mice 
were sacrificed by cervical dislocation. Particles were explanted, fixed in 4% 
paraformaldehyde (Merck), dehydrated and embedded in methyl methacrylate (L.T.I. 
Bilthoven) for sectioning. Undecalcified sections were processed on a histological diamond 
saw (Leica) and sections were stained with methylene blue and basic fuchsin to visualize bone 
formation. Quantitative histomorphometry was performed by pseudocoloring (bone in green, 
scaffolds in red) scanned images of high-resolution (7200 dpi) micrographs (Pathscan Enabler 
IV), after which the percentage of bone per scaffold area was determined using the pixel 
count option in Photoshop CS5 (Adobe).  
Masson’s Trichrome staining 
hMSC/BCP constructs were firstly fixed in 4% formaldehyde at 4 °C overnight before being 
decalcified in EDTA/PBS (pH 7.5) for 4 weeks. The decalcified implants were subsequently 
paraffin embedded and sectioned at 6µm. For Masson's Trichrome analysis, the sections were 
deparaffinised in Histoclear™ (Laborimpex, Brussels, Belgium), then methanol and rinsed 
with distilled water. The slides were then immersed in Weigerts iron hematoxylin solution for 
10 minutes before rinsing in warm running tap water for 10 minutes. The sections were 
subsequently stained with ponceau-acid fuchsin solution (0.5% ponceau BS, 0.5% acid 
fuchsin in 10% acetic acid) for 15 minutes, washed in distilled water and differentiated in 5% 
phosphomolybdic acid 5% phosphotungstic acid solution for 15 minutes. The sections were 
then transferred directly to Masson’s green solution (Klinipath, Olen, Belgium) for 10 
minutes before differentiation for 5 minutes in 1% acetic acid. The sections were then rinsed 
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in distilled water, dehydrated through graded alcohol before being cleared in Histoclear for 2 
minutes and mounted in Pertex. 
Statistics 
Data were analyzed in SPSS (PASW statistics) using one-way Anova followed by Tukey’s 
multiple comparison test (P<0.05). 
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Results 
IGF-1 increases proliferation of hMSCs and MG-63 cells in the absence of serum 
To investigate the effect of IGF-1 on proliferation of hMSCs, cells were cultured in the 
presence of 10-150 ng/mL rhIGF-1 for 4 days, after which metabolic activity, as a measure 
for cell number, was determined. Since IGF-1 was previously shown to enhance proliferation 
of human osteoblasts in serum-free medium and the MG-63 cell line is frequently used as a 
model system for these cells, we used this cell line as a control. None of the used IGF-1 
concentrations affected proliferation of MG-63 cells or hMSCs (supplementary figure 1) in 
culture medium containing FBS. In contrast, when FBS was removed from the medium, a 
clear dose-dependent increase in proliferation was observed for both cell types, although MG-
63 cells showed a stronger response (50% increase in cell number) than hMSCs (20% 
increase in cell number) (figure 1a).  
IGF-1 enhances differentiation of hMSCs in the absence of serum but decreases ALP 
expression of MG-63 cells 
Then, to investigate if IGF-1 also has a positive effect on osteogenic differentiation of these 
cells, hMSCs and MG-63 cells were cultured in the presence of rhIGF-1 with concentrations 
ranging from 10-150 ng/mL and ALP levels were determined. Again, in the presence of FBS 
there was no effect of IGF-1 (supplementary figure 2), but in the absence of FBS, a dose-
dependent increase in ALP expression was observed (figure 1b). In line with this, treatment of 
hMSCs with 100 ng/mL rhIGF-1 for a period of 1-10 days, resulted in an increase in the 
expression of bone marker genes such as osteonectin, collagen type I, ALP. Runx2 expression 
was increased, but this was not significant and osteocalcin and S1004A were not affected, as 
demonstrated by qPCR (figure 2a). Again, IGF-1 did not induce expression of osteogenic 
genes when FBS was supplemented to the medium (data not shown). In contrast, ALP 
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expression of MG-63 cells was significantly decreased with all concentrations of IGF-1, both 
in FBS-supplemented and FBS-free medium, although in the latter the effect was clearly 
stronger (supplementary figure 2 and figure 1b). qPCR on MG-63 cells, using a concentration 
of 100 ng/mL rhIGF-1, confirmed the effect on ALP gene expression, although at day 10, 
ALP expression was slightly higher in IGF-1 treated cells. Expression of other osteogenic 
markers, such as runx2, collagen type I and osteonectin, was also increased by IGF-1 at later 
timepoints (day 5-10), whereas there was no change in expression of osteocalcin (figure 2b), 
and S1004A expression was decreased. These data show that IGF-1 increases osteogenic 
differentiation of both MG-63 cells and hMSCs. 
IGF-1 enhances BMP-2-induced mineralization of hMSCs 
In mouse knock-out models, IGF-1 was suggested to correlate with matrix formation and 
therefore we examined the effect of IGF-1 on mineralization of hMSCs. Previously, BMP-2 
has been demonstrated to increase mineralization of hMSCs, which was confirmed here for 
concentrations of 75 and 100 ng/mL (figure 3a), and therefore we also examined synergistic 
effects between these two growth factors. hMSCs were cultured in mineralization medium 
supplemented with 75 ng/mL BMP-2, 100 ng/mL IGF-1 or both. After 14 days, neither BMP-
2 nor IGF-1 increased calcium deposition, but, compared to control, combined treatment 
resulted in significant higher amounts of calcium (figure 3b). After 21 days a slight increase 
in calcium deposition was observed using BMP-2 or IGF-1 alone, but this was not significant. 
In contrast, addition of both factors resulted in a synergistic increase in calcium deposition, 
suggesting an interaction between these two factors. To investigate the mechanism behind the 
effects of IGF-1, mineralized samples were examined using Raman spectroscopy and 
scanning electron microscopy (SEM). Figure 3c shows Raman spectra after 28 days of 
culture. The calcium phosphate peak (961 cm
-1
) observed in cells cultured with BMP-2 and 
BMP-2/IGF-1 was higher compared to control, but no differences were observed between 
 Page 14 of 37
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
IN
SU
LI
N
-L
IK
E-
G
RO
W
TH
-F
A
CT
O
R-
I E
N
H
A
N
CE
S 
PR
O
LI
FE
RA
TI
O
N
 A
N
D
 D
IF
FE
RE
N
TI
A
TI
O
N
 O
F 
H
U
M
A
N
 M
ES
EN
CH
Y
M
A
L 
ST
RO
M
A
L 
CE
LL
S 
IN
 V
IT
RO
 (d
oi:
 10
.10
89
/te
n.T
EA
.20
12
.05
22
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
15 
15 
 
BMP-2 and BMP-2/IGF-1. Similarly, SEM images showed large amounts of mineralized 
nodules in both BMP-2 and BMP-2/IGF-1 groups, but we did not find differences in size or 
frequency of the nodules (figure 3d).  
AdIGF-1 increases runx2 and osteonectin expression in vitro 
To investigate the effects of secreted IGF-1 on in vitro differentiation of hMSCs, cells were 
adenovirally transduced with IGF-1 and after 5 days of culture, gene expression levels of 
runx2, collagen type I, ALP and osteonectin were examined. As depicted in figure 4a, 
transduction with IGF-1 resulted in high expression levels of IGF-1 already after 2 days. 
Compared to control, GFP transduced cells, IGF-1 also increased osteonectin and runx2 
expression, but collagen type I levels were not affected and ALP levels were only slightly but 
not significantly increased after 5 days. The amount of secreted IGF-1 after adenoviral 
transduction was determined every 3 days for a total period of 15 days, and at the time of 
qPCR (2 and 5 days), cells secreted approximately 6 or 20 ng/mL IGF-1 respectively (figure 
4b).  
Co-transduction with adIGF-1 and adBMP-2 enhances BMP-2 secretion and in vivo bone 
formation 
Then, to investigate the effects of IGF-1 and synergistic effects of IGF-1 and BMP-2 on in 
vivo bone formation, hMSCs were adenovirally transduced with IGF-1 or BMP-2, or both 
(IGF-1/BMP-2). As a control, cells were transduced with GFP. As a control, cells from the 
same transduction batch were kept in culture in vitro and the cumulative release profile was 
determined by collecting medium every 3 days for a total period of 30 days. As depicted in 
figure 5a, the release of IGF-1 was significantly lower in co-transduced cells but, surprisingly, 
the secretion of BMP-2 was significantly increased in cells transduced with both BMP-2 and 
IGF-1, compared to cells transduced with BMP-2 alone. Therefore, to investigate the interplay 
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between adIGF-1 and adBMP-2 transductions in more detail, hMSCs were co-transduced with 
IGF-1 (MOI 1000) and a range of BMP-2 (MOI 31.25 – 250). Figure 5b shows the 
cumulative release of IGF-1 and BMP-2 from single-transduced and co-transduced cells. As 
expected, transduction with IGF-1 alone, resulted in higher secretion of IGF-1 compared to 
co-transduced cells, and this decreases with increasing concentrations of BMP-2. Secretion of 
BMP-2 also increased with increasing MOI, but surprisingly, in samples with a low MOI of 
adBMP-2, BMP-2 secretion was higher after co-transduction with both IGF-1 and BMP-2, 
whereas secretion levels were similar upon co-transduction of adIGF-1 and high 
concentrations of adBMP-2. To determine if overexpression of IGF-1 induces secretion of 
BMP-2 via a feedback mechanism, BMP-2 secretion by adIGF-1 transduced cells was 
examined, but these levels were comparable to control (GFP).  
In line with these findings, after 6 weeks of implantation, bone formation in the IGF-1/BMP-2 
group was higher than in the BMP-2 group (39% and 48% respectively). In contrast, no bone 
was formed in the GFP group, whereas some scaffolds in the IGF group displayed a low 
percentage of bone (0.6%) (figure 5c). The in vitro release profile suggests that the increased 
amounts of bone may be related to enhanced BMP-2 secretion. On the other hand, histological 
observations showed that bone in the BMP-2/IGF-1 group displayed a lower level of 
mineralization, indicating a less mature state, compared to BMP-2 or IGF-1 groups. In both 
BMP-2 and BMP-2/IGF-1 groups, bone marrow was formed inside the scaffolds pores, but 
the marrow was more densely packed and more granular in the BMP-2/IGF-1 group (arrows, 
figure 6). The less mature state of the bone in the BMP-2/IGF-1 group was confirmed by 
Masson’s Trichrome staining (figure 7), which showed that only the BMP-2 group contained 
areas of mature bone (red). 
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Discussion 
Numerous studies have investigated the effects of IGF-1 on MSCs from different sources and, 
whereas some studies show increased proliferation and differentiation of hMSCs in response 
to IGF-1, others fail to show an effect. Culture protocols vary greatly between these studies, 
which makes it difficult to compare them. Walsh et al. reported that a concentration of 10 
ng/mL IGF-1 had no effect on proliferation or ALP expression of CFU-Fs [20] whereas a 
study by Koch et al. showed increased expression of runx2 and collagen type I after 
adenoviral transductions, with the levels of secreted IGF-1 around 120 ng/mL 10 days post-
transduction [22]. These data suggest that low concentrations of IGF-1 do not affect 
proliferation or differentiation of hMSCs, which was also demonstrated by our ALP 
experiments, which show a clear dose-dependent effect. In addition, we show here that with a 
concentration of 100 ng/mL rhIGF-1, expression of osteonectin and runx2 increase 3-5 fold, 
whereas adenoviral overexpression (resulting in 20 ng/mL secreted IGF-1 5 days post-
transduction) only slightly increased runx2 and osteonectin expression and did not affect 
collagen type I. Similarly, treatment with rhIGF-1 resulted in an increase in ALP levels after 5 
days of culture, which could not be repeated using adenoviral overexpression of IGF. Other 
studies using scaffold-release systems that result in a high concentration of IGF-1 (80-100 
ng/mL) indeed also show positive effects on proliferation and osteogenic differentiation [23, 
24]. 
The presence of serum in the medium also plays a key role when investigating the effects of 
IGF-1. In the absence of serum, we found an increase in both proliferation and differentiation 
of hMSCs, whereas in the presence of serum IGF-1 had no effect. Most likely, serum contains 
proteins that neutralize IGF-1 function, such as IGF binding proteins (IGFBPs) and the acid-
labile subunit (ALS), which were shown to inhibit IGF-1 function in mouse models. 
Overexpression of ALS [32], IGFBP1 [33], -2 [34], -3 [35] or -5 [36] resulted in deficiencies 
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in the skeleton, such as reduced body weight, growth retardation, diminished mineralization, 
decreased cortical thickness and reduced cortical bone volume. Although total IGF-1 serum 
levels were not affected in these models, the amounts of extracellular fluid IGF-1 available to 
bind to tissue receptors were decreased, thus suggesting that these proteins inhibit IGF-1 
activities.  
The potential of IGF-1 to improve fracture healing has been demonstrated in in vivo models, 
but studies are not consistent. Both local and systemic delivery of rhIGF-1 were reported to 
enhance bone formation in a distraction osteogenesis mouse model [37], but systemic 
administration in a rat femoral defect had no effect [38]. Also, systemic delivery increased 
IGF-1 serum levels, which could potentially result in negative side effects. Therefore, local 
application using controlled release systems offers a better alternative, especially for tissue 
engineering applications, but also in this case reports are not consistent. Meinel et al. showed 
enhanced bone formation by IGF-1-releasing scaffolds [39], whereas a study by Laffargue et 
al. shows a slight increase at best [40]. So far, better results are obtained using dual release 
systems. Implants releasing both IGF-1 and TGF-β resulted in more advanced bone 
remodeling in fracture models in rats and sheep [41, 42] and the combination of IGF-1 and 
platelet-derived growth factor (PDGF) also improved bone regeneration [43, 44]. BMP-2 is 
the main player in stimulating fracture repair, and therefore we investigated the combined 
treatment/secretion of IGF-1 and BMP-2 [45]. We demonstrate that IGF-1 potentiates BMP-
2-induced mineralization in vitro, whereas IGF-1 alone does not affect mineralization, thus 
showing a synergistic effect. This is in line with a mouse model, which demonstrates that 
IGF-1 is involved in mineralization [6]. Unexpectedly, using a range of BMP-2 
concentrations, mineralization of hMSCs (donor 134A; donor numbers correspond to our 
internal databank) was increased by 75-100 ng/mL BMP-2, but in a second study (donor 102) 
using both BMP-2 and IGF-1, a concentration of 75 ng/mL BMP-2 did not significantly affect 
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calcium deposition, although synergistic effects between BMP-2 and IGF-1 were still 
observed. We speculate that this is a donor-dependent effect. 
In addition to these in vitro data, we found higher amounts of newly formed bone by cells co-
transduced with both IGF-1 and BMP-2, compared to BMP-2 alone. Surprisingly, the amount 
of BMP-2 secreted by co-transduced cells was higher than by cells transduced with BMP-2 
alone. Additional experiments using a range of adBMP-2 MOI’s also demonstrated that, when 
using low MOI, the secretion of BMP-2 increases upon co-transduction, suggesting that 
adIGF-1 facilitates adBMP-2 transduction, BMP2 gene expression or BMP2 protein secretion. 
This is interesting, since secreted IGF-1 is reduced upon co-transduction with adBMP-2, and 
also negatively correlates with increasing MOI’s of adBMP-2. Further experiments are 
required to investigate this in more detail. Overexpression of IGF-1 alone resulted in small 
amounts of new bone in vivo, but did not lead to clinically relevant amounts of bone. Due to 
the increase in BMP-2 secretion after co-transduction it is difficult to draw conclusions 
regarding the effect of IGF-1 on BMP-2-induced bone formation. We have previously 
demonstrated that scaffold incorporation of 1-40 µg rhBMP-2 does not result in 
morphological differences of newly formed bone, although more bone marrow was found 
with increasing concentrations of BMP-2 [46]. Therefore, the increased BMP-2 secretion 
probably accounts for the increase in bone and bone marrow, however, it is unlikely that the 
osteoid appearance of the bone is due to higher concentrations of BMP-2, which suggests that 
IGF-1 has a negative effect on the maturation of bone.  
Conclusions 
We demonstrated that IGF-1 enhances proliferation and osteogenic differentiation of both 
hMSCs and MG-63 in vitro, but its effects are highly dependent on the used concentration and 
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the presence of serum. In vivo, IGF-1 had small effects on bone formation of hMSCs, 
although it seemed to inhibit the maturation of BMP-2-induced bone formation. 
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Figure Legends 
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Figure 1. IGF-1 increases proliferation and differentiation of hMSCs and MG63 cells, 
but only in the absence of FBS. hMSCs and MG63 cells were cultured in the presence of 
various concentrations rhIGF-1 and proliferation and ALP activity were assessed after 4 days. 
When FBS was supplemented to the medium, IGF-1 did not affect proliferation (data not 
shown), but in the absence of FBS, IGF-1 significantly increased cell number (a). In hMSCs,  
IGF-1 also significantly increased ALP expression of hMSCs, whereas, in contract, in MG-63 
cells, IGF decreased ALP levels (b). Alamar blue data is represented relative to ctrl. * P <0.05 
compared to ctrl, ** P <0.01 compared to ctrl. CDP-star data is represented relative to ctrl. * 
P <0.05 compared to ctrl, ** P <0.01 compared to ctrl. 
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Figure 2. IGF-1 induces expression of osteogenic genes in hMSCs and MG-63. hMSCs 
and MG-63 cells were cultured in the presence of 100 ng/mL rhIGF, but in the absence of 
FBS for 1-10 days, after which gene expression levels were analyzed by qPCR. IGF-1 
significantly increased gene expression of Collagen type I, osteonectin and ALP and non-
significantly increased runx2 expression in hMSCs. No effect was found on osteocalcin and 
S100A4 (a). In MG-63 cells, IGF-1 significantly increased gene expression of Runx2, 
collagen type I and osteonectin, did not affect osteocalcin levels and, at day 10, decreased 
S1004A levels. In line with biochemical assays, ALP levels were decreased at early 
timepoints, but increased at later timepoints. Data is represented relative to ctrl. * P <0.05 
compared to ctrl, ** P <0.01 compared to ctrl. 
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Figure 3. IGF-1 synergistically acts with BMP-2 to induce mineralization in hMSCs. 
hMSCs were cultured in mineralization medium in the presence of various concentrations of 
BMP-2. 75 and 100 ng/mL BMP-2 significantly increased calcium deposition, whereas 
concentrations below had no effect (a). Then, using hMSCs from a second donor, hMSCs 
were cultured in mineralization medium in the presence of 75 ng/mL BMP-2 and/or 100 
ng/mL IGF-1. After 2 and 3 weeks, calcium deposition was determined. After 2 weeks, there 
was no effect of either BMP-2 or IGF-1, and after 3 weeks both BMP-2 and IGF-1 alone had 
a small but non-significant effect on calcium deposition, whereas the combination of BMP-2 
and IGF-1 significantly increased the amount of calcium deposited both after 2 and 3 weeks 
(b). Raman spectra of hMSCs cultured for 28 days in mineralization medium, with or without 
BMP-2 or BMP-2/IGF-1 showed no differences in proteins or nodule size (c). In addition, 
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electron micrographs showed no differences in mineralized ECM produced by hMSCs in A) 
control, B) BMP-2, and C) BMP-2 + IGF-1 after 10 and 17 days of culture. Arrow in (c) 
indicates the Raman band around 961 cm
-1
, reflecting the presence of ν1 vibration of 
phosphates. Spectra are offset for clarity. T1 = 10 days, T2 = 17 days; scale bar = 10 μm. * 
P<0.05 compared to ctrl. 
 Page 29 of 37 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
IN
SU
LI
N
-L
IK
E-
G
RO
W
TH
-F
A
CT
O
R-
I E
N
H
A
N
CE
S 
PR
O
LI
FE
RA
TI
O
N
 A
N
D
 D
IF
FE
RE
N
TI
A
TI
O
N
 O
F 
H
U
M
A
N
 M
ES
EN
CH
Y
M
A
L 
ST
RO
M
A
L 
CE
LL
S 
IN
 V
IT
RO
 (d
oi:
 10
.10
89
/te
n.T
EA
.20
12
.05
22
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
30 
30 
 
 
 
Figure 4. Adenoviral transduction with IGF-1 increases expression of runx2 and 
osteonectin. hMSCs were transduced with adIGF-1 and after 5 days of culture, Runx2, 
collagen type I, ALP and osteonectin gene expression levels were determined. Overexpression 
of IGF-1 resulted in high expression of IGF-1, and, compared to the control (adGFP), 
significantly increased osteonectin levels, and runx2 levels after 5 days, but collagen type I 
expression was not affected. ALP levels were slightly increased after 5 days, but this was not 
significant (a). Every 3 days, levels of secreted IGF-1 were determined by ELISA, and 
showed that after 5 days, 14 ng/mL IGF-1 was secreted and that cells kept releasing IGF-1 
until at least day 15 (b). * P<0.05 compared to ctrl; ** P<0.01 compared to ctrl; T1 = 2 days, 
T2 = 5 days.  
 Page 30 of 37
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
IN
SU
LI
N
-L
IK
E-
G
RO
W
TH
-F
A
CT
O
R-
I E
N
H
A
N
CE
S 
PR
O
LI
FE
RA
TI
O
N
 A
N
D
 D
IF
FE
RE
N
TI
A
TI
O
N
 O
F 
H
U
M
A
N
 M
ES
EN
CH
Y
M
A
L 
ST
RO
M
A
L 
CE
LL
S 
IN
 V
IT
RO
 (d
oi:
 10
.10
89
/te
n.T
EA
.20
12
.05
22
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
31 
31 
 
 
 
Figure 5. Co-transduction of IGF-1 and BMP-2 facilitates BMP-2 secretion and results 
in increased amounts of bone formation in vivo. hMSCs were transduced in vitro with IGF-
1, BMP-2 or both and implanted in vivo. The concentration of secreted IGF-1, as tested in 
vitro, was reduced upon co-transduction of IGF-1 and BMP-2, whereas the secretion of BMP-
2 was increased upon co-transduction (a). To investigate this in more detail, hMSCs were 
transduced with 1000 MOI adIGF-1, 31.2-250 MOI adBMP-2 or both. The next day medium 
was changed for basic medium and after 3, 7, 14 and 21 days, medium was collected and the 
amount of secreted IGF-1 and/or BMP-2 were determined. Indeed, secretion of IGF-1 was 
reduced with increasing concentrations of co-transduced BMP-2, and transduction of BMP-2 
alone resulted in increased secretion of BMP-2 with increasing MOI, with a maximum of an 
MOI of 125. However, co-transductions of adIGF-1 (MOI 1000) and various concentrations 
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of BMP-2 resulted in an increase in BMP-2 secretion, compared to transduction with BMP-2 
alone (b). Cells transduced with BMP-2, IGF-1 or both were then implanted in nude mice and 
after 6 weeks, small amounts of bone were observed in the IGF-1 group (0.60% of bone / 
scaffold area), whereas no bone was found in the control (adGFP transduced). Transduction 
with BMP-2 resulted in high amounts of bone (39% bone / scaffold area), which was 
increased even further by co-transduction of BMP-2 and IGF-1 (48% bone / scaffold area) (c). 
* P<0.05 compared to ctrl; ** P<0.01 compared to ctrl; ## P<0.01 compared to IGF-1+BMP-
2; asterisks and circles in (c) represent outliers. 
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Figure 6. Histological overview of in vivo bone formation. No bone was formed in the GFP 
group whereas in the IGF group small amounts of mature bone were observed in some 
implants. Large amounts of mature bone were formed in the BMP-2 group, whereas in the 
BMP-2/IGF-1 group, large amounts of osteoid were formed. In addition, in both the BMP-2 
and the BMP-2/IGF-1 group, large amounts of bone marrow (arrows) occupied spaces 
between the scaffolds, but this was denser and more granular in the BMP-2/IGF-1 group. 
Magnifications; top 40X, middle 100X, bottom 200X.  
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Figure 7. Mature bone was observed in the BMP-2 group, but not in the BMP-2/IGF-1 
group. Mason’s Trichrome staining of decalcified in vivo samples showed parts of mature 
bone formation (red) in the BMP-2 group. This was surrounded by immature bone (green), 
which was also formed in the BMP-2/IGF-1 group. Scale bar = 1 mm.  
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Supplementary data 
Supplementary figure 1. IGF-1 does not affect proliferation or differentiation of hMSCs in 
the presence of FBS. 
Supplementary figure 2. IGF-1 does not affect proliferation of MG-63 cells, but decreases 
ALP levels in the presence of FBS.  
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Table 1. Primer sequences 
Gene Primer set 
18s F-CGGCTACCACATCCAAGGAA 
R-GCTGGAATTACCGCGGCT 
IGF-1 F-CTTCAGTTCGTGTGTGGAGACA 
R-CGCCCTCCGACTGCTG 
Collagen 
type I 
F-AGGGCCAAGACGAAGACATC 
R-AGATCACGTCATCGCACAACA 
Runx2 F-ATGGCGGGTAACGATGAAAAT 
R-ACGGCGGGGAAGACTGTGC 
ALP F-GACCCTTGACCCCCACAAT 
R-GCTCGTACTGCATGTCCCCT 
Osteocalcin F-GGCAGCGAGGTAGTGAAGAG 
R-GATGTGGTCAGCCAACTCGT 
Osteonectin F-ACTGGCTCAAGAACGTCCTG 
R-GAGAGAATCCGGTACTGTGG 
S100A4 F-AGCTTCTTGGGGAAAAGGAC 
R-CCCCAACCACATCAAGAGG 
 
 
 
 Page 37 of 37 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
IN
SU
LI
N
-L
IK
E-
G
RO
W
TH
-F
A
CT
O
R-
I E
N
H
A
N
CE
S 
PR
O
LI
FE
RA
TI
O
N
 A
N
D
 D
IF
FE
RE
N
TI
A
TI
O
N
 O
F 
H
U
M
A
N
 M
ES
EN
CH
Y
M
A
L 
ST
RO
M
A
L 
CE
LL
S 
IN
 V
IT
RO
 (d
oi:
 10
.10
89
/te
n.T
EA
.20
12
.05
22
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
